Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ivosidenib (Tibsovo) is indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test. It is used in treating newly diagnosed Acute Myeloid Leukemia (AML), relapsed or refractory AML, myelodysplastic syndromes, and locally advanced or metastatic cholangiocarcinoma.
• Four systematic reviews/meta-analyses provided insights into Tibsovo's safety and effectiveness across its various indications.
• In terms of effectiveness for newly diagnosed AML patients with IDH mutations, Tibsovo demonstrated a complete response rate of 47% when used alone but showed improved survival outcomes when combined with azacitidine.
• For relapsed or refractory AML cases, the complete response rate was lower at 21%, indicating that Tibsovo may not be optimal as monotherapy due to low CR rates in this population group; however, it still represents a promising option.
• Compared to other existing targeted therapies such as azacitidine monotherapy, combining Tibsovo with hypomethylating agents like azacitidine yielded better overall survival hazard ratios, suggesting superior effectiveness especially among those ineligible for first-line induction chemotherapy.
• The most frequently occurring adverse events associated with using Ivosidenib are gastrointestinal issues and hematologic adverse events. However, these side effects appear manageable, particularly when administered alongside azacitidine, which has shown comparatively lower infection rates.